RE:RE:RE:RE:RE:RE:RE:How Barclays Capital values Small Cap Oncology namesHey! I wrote fast track here a few hours before the real fast track news!!! Joking!
So great news, but frustrating at the same time. Timing of the financing looks uglier, but I think they had no idea they were about to get this news. That being said, it is also shame on the market (analysts, funds, big investors) because it has not been able to see the potential in oncology. Now let's hope that the potential will materialize and that the SP will make us all forget about this financing in the long run.
jfm1330 wrote: Thera really need to explore that option a soon as possible and if early positive results would push the SP up next fall, they could really put that on
fast track if early tests would show that their peptide is suitable for use with radioisoptopes. Wake up!
https://www.cmaj.ca/content/cmaj/190/49/E1461.full.pdf
jfm1330 wrote: The thing is that validating the feasability of linking isotopes to their peptide is very easy and quick to do. There are universities in the province of Qubec that are doing it with Tyr3 octreotide peptide. It would be easy to collaborate with them to validate the feasability of linking the isotope to their peptide. Then, if it works, it would be easy to inject that PDC to a rat with a xenograft tumor and do a PET scan in a few minutes. This is not a big and costly project. They just need to be aware of that possibility and act on it.
If these two easy steps would be positive, then it would require more money and time to get the imaging option with Ga68 approved by authorities, and much more money and time to develop a therapeutic PDC with Lu177. But the first two validation steps are easy, quick and not expensive. They just need to initiate contact with the university and do it. For them to have the imaging option would be so helpful. First and most importantly for patient selection for treatment, then for monitoring treatment efficacy.